Eli Lilly and Nvidia announced a multiyear partnership to build an AI drug discovery lab, committing up to $1 billion over five years to compute, infrastructure and joint model development. Lilly said the collaboration will place Nvidia engineers alongside Lilly scientists to generate large‑scale biological data and construct models to accelerate target identification and lead optimization. The pact builds on earlier Lilly–Nvidia collaborations and reflects industry moves to integrate bespoke compute with pharma pipelines.